After ICAAC: Some More Thoughts on Eravacycline in cUTI and IGNITE-2
When a well-designed pivotal Phase 3 trial fails to show NI, it demands an explanation. While awaiting the company’s analysis of the data, many possible explanations are bandied about. So it was not surprising that the eravacycline cUTI study (IGNITE-2) Continue reading After ICAAC: Some More Thoughts on Eravacycline in cUTI and IGNITE-2